Although most studies supported that BC with homogeneously HER2 positivity benefited more from trastuzumab treatment [13], predictive relationship between the genetic heterogeneity and treatment response was not found in early stage breast cancers in the adjuvant setting [36]. The gene discussed is ERBB2; the disease is breast carcinoma.